Your browser doesn't support javascript.
loading
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).
Griessbach, Alexandra; Chammartin, Frédérique; Abela, Irene A; Amico, Patrizia; Stoeckle, Marcel P; Eichenberger, Anna L; Hasse, Barbara; Braun, Dominique L; Schuurmans, Macé M; Müller, Thomas F; Tamm, Michael; Audigé, Annette; Mueller, Nicolas J; Rauch, Andri; Günthard, Huldrych F; Koller, Michael T; Trkola, Alexandra; Epp, Selina; Amstutz, Alain; Schönenberger, Christof M; Taji Heravi, Ala; Kusejko, Katharina; Bucher, Heiner C; Briel, Matthias; Speich, Benjamin.
Affiliation
  • Griessbach A; Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Chammartin F; Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Abela IA; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Amico P; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Stoeckle MP; Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
  • Eichenberger AL; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Hasse B; Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Braun DL; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Schuurmans MM; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Müller TF; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Tamm M; Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
  • Audigé A; Nephrology Clinic, University Hospital Zurich, Zurich, Switzerland.
  • Mueller NJ; Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland.
  • Rauch A; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Günthard HF; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Koller MT; Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Trkola A; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Epp S; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
  • Amstutz A; Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
  • Schönenberger CM; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Taji Heravi A; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Kusejko K; Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Bucher HC; Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Briel M; Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Speich B; Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Open Forum Infect Dis ; 10(4): ofad150, 2023 Apr.
Article de En | MEDLINE | ID: mdl-37035486
ABSTRACT
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%-100.0%]) in individuals with different levels of immunosuppression (difference, -2.8% [95% CI, -6.8% to 1.3%]).
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials Langue: En Journal: Open Forum Infect Dis Année: 2023 Type de document: Article Pays d'affiliation: Suisse
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials Langue: En Journal: Open Forum Infect Dis Année: 2023 Type de document: Article Pays d'affiliation: Suisse